Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine.

Richard Friedrich Radlberger* (First author), I Sakic, Tobias Moser (Co-author), Georg Pilz (Co-author), Andrea Harrer (Co-author), Peter Wipfler (Last author)

*Corresponding author for this work

Research output: Contribution to journalOriginal Articlepeer-review

5 Citations (Web of Science)
Original languageEnglish
Pages (from-to)102727
JournalMultiple Sclerosis and Related Disorders
Volume48
DOIs
Publication statusPublished - 2021

Keywords

  • MULTIPLE-SCLEROSIS
  • ORAL CLADRIBINE
  • MS

Cite this